Intercellular Adhesion Molecule 1 (CD54) Market Size, Definition 2016 Global Markets Direct's, 'Intercellular Adhesion M

Intercellular Adhesion Molecule 1 (CD54) Market Share, Size,
Treatment, Symptoms, Pipeline Review, H1 2016: Radiant
Insights
Summary
Global Markets Direct's, 'Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Pipeline Review, H1 2016', provides in depth analysis on Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group
Rhinovirus Receptor or CD54) targeted pipeline therapeutics.
The report provides comprehensive information on the Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group
Rhinovirus Receptor or CD54) , targeted therapeutics, complete with analysis by indications, stage of development,
mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research and development history and latest
news and press releases. Additionally, the report provides an overview of key players involved in Intercellular
Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics development
and features dormant and discontinued projects.
Click For Report Details @ http://www.radiantinsights.com/research/intercellular-adhesion-molecule-1
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (ICAM-1
or Major Group Rhinovirus Receptor or CD54)
- The report reviews Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)
targeted therapeutics under development by companies and universities/research institutes based on information
derived from company and industry-specific sources